Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of #ProstateCancer : A prospective, multicenter study. #BeyondTheAbstract on UroToday > bit.ly/3dyPZtr Urologic Oncology Eric Klein yair lotan Jason Hafron Mark Stovsky

Future directions in systemic treatment of metastatic hormone-sensitive #ProstateCancer . #BeyondTheAbstract with Arun Azad, Kenneth Chen Singapore General Hospital (SGH), and Louise Kostos Peter Mac Cancer Centre. #ReadNow on UroToday > bit.ly/3Lwnb1e University of Melbourne

Comparison of superpulse thulium fiber laser vs. holmium laser for ablation of renal calculi in an in vivo porcine model. Andyshea Afyouni UCI Urology presents results of this study on UroToday > bit.ly/3QQXIAx UC Irvine

PSA-directed treatment for BCR. #APCCC22 presentation by Neha Vapiwala Penn Medicine. #WatchNow on UroToday >
bit.ly/3pNu8AY APCCC22 silke gillessen aurelius omlin

Practice changing abstracts in upper tract #UrothelialCarcinoma , a review from #AUA22 . Firas Petros, MD, FACS The University of Toledo joins Sam S. Chang MD, MBA Vanderbilt-Ingram Cancer Center data released at the 2022 Amer. Urol. Assn. annual meeting > bit.ly/3s5YaBm

When low-volume on conventional imaging goes into high-volume on next-generation imaging in #mHSPC . Karim Fizazi GustaveRoussy joins Alicia Morgans, MD, MPH Dana-Farber in this discussion on the management of metastatic hormone-sensitive #ProstateCancer > bit.ly/3NdilFi

The use of PARP inhibitors in castrate-resistant #ProstateCancer . Elena Castro & Joaquin Mateo joins Alicia Morgans, MD, MPH Dana-Farber to discuss, genetic testing, PARP inhibitors, and data from the #PROpel and #MAGNITUDE trials. #WatchNow > bit.ly/3HJlqMm APCCC22

Targeting mechanisms of lethal #ProstateCancer , the 2022 #PCF #TACTICAL Team Science Award. Charles Ryan and Howard Soule Prostate Cancer Foundation discuss the progress of this award campaign in a conversation on UroToday > bit.ly/3Clfvw3 PCF Science

The management of high-risk localized disease and double therapy in the #mCRPC setting. Andrey Soares H.I.Albert Einstein and Phillip Koo, MD Banner Health discuss challenges and opportunities in pts with HR localized disease in #LatinAmerica and #ARASENS > bit.ly/3lLP5KJ

Optimal treatment sequencing in #mCRPC . #APCCC22 presentation by Maha Hussain, MD, FACP, FASCO Lurie Cancer Center. #WatchNow on UroToday > bit.ly/3CaEOR7 APCCC22 @SilkeGillessen aurelius omlin

Is there still a role for cytoreductive nephrectomy? Analysis from the #CARMENA trial - #JournalClub discussion with Christopher Wallis University of Toronto & Zach Klaassen GeorgiaCancerCenter. #WatchNow on UroToday > bit.ly/3BO8J0b

The uptake of new treatment options for #mHSPC in real life -- Education, access, use, and diversity. #APCCC22 presentation by Andrew Armstrong Duke Cancer. #WatchNow on UroToday > bit.ly/3RH2AJG APCCC22 silke gillessen aurelius omlin

Clinical integration of #MachineLearning for curative-intent radiation treatment of patients with #ProstateCancer . Presented by Alejandro (Ale) Berlin Princess Margaret Cancer Centre. #ASTRO22 coverage by Zach Klaassen GeorgiaCancerCenter > bit.ly/3eYTBWm ASTRO

Combination and novel pharmacologic agents for #OAB . #BeyondTheAbstract on UroToday ArshiaAalami Nitya > bit.ly/3crAMtL Albert Einstein College of Medicine
#CurrentUrologyReports Farzaan Kassam

Transcriptomic features of cribriform and intraductal carcinoma of the prostate. Presentation by Zaeem Lone Cleveland Clinic Lerner College of Medicine. #ASTRO22 written coverage by Zach Klaassen GeorgiaCancerCenter > bit.ly/3zyHl6f ASTRO

M0 #CPRC : Overview of treatment options. #APCCC22 presentation by Eleni Efstathiou Houston Methodist. #WatchNow on UroToday > bit.ly/3AfZtRQ silke gillessen aurelius omlin APCCC22 Elena Castro

Abdominal aorto-Iliac calcification burden assessment using deep convolutional neural networks for prediction of cardiovascular risk among #ProstateCancer patients undergoing stereotactic body radiotherapy. William C Chen
UCSF Helen Diller Family Comprehensive Cancer Ctr. #ASTRO22 > bit.ly/3zaxP91 ASTRO

🔶PSA screening rates 📉 among men aged 40 years or older in the US Veterans Health Administration
🔶Facilities with higher PSA screening rates had lower subsequent rates of metastatic #prostatecancer

JAMA Oncology OncoAlert Prostate Cancer Foundation European Association of Urology (EAU) ASCO National Comprehensive Cancer Network (NCCN)

jamanetwork.com/journals/jamao…

Advances in treatment options for BCG unresponsive CIS and papillary non-muscle invasive #BladderCancer . Sam S. Chang MD, MBA Vanderbilt Urology joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss the results of the #QUILT 3.032 study in this conversation on UroToday > bit.ly/3Blinss